Shield Therapeutics PLC Block Listing Application (7506E)

TIDMSTX

RNS Number : 7506E

Shield Therapeutics PLC

02 March 2020

Shield Therapeutics plc

("Shield" or the "Group")

Block Listing Application

London, UK, 02 March 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer(R) (ferric maltol), has today made an application to the London Stock Exchange for a block listing of 2,500,000 ordinary shares of 1.5 pence each in the Company ("Block Listing Shares") to be admitted to trading on the London Stock Exchange ("Admission") and to be split between the schemes listed below.

The 2,500,000 Block Listing Shares are to be issued under the following schemes:

   --     Shield Therapeutics Retention Share Plan 
   --     Shield Therapeutics plc 2016 Company Share Option Plan 
   --     The Shield Therapeutics plc 2016 Long Term Incentive Plan 
   --     Shield Therapeutics Retention and Performance Share Plan 

Admission is expected to occur on 6 March 2020.

For further information please contact:

 
 Shield Therapeutics plc                             www.shieldtherapeutics.com 
 Carl Sterritt, Chief Executive 
  Officer                                                   [phone] 
 Tim Watts, Chief Financial 
  Officer 
 
 
   Nominated Advisor and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                    [phone] 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                     [phone] 
 
  Financial PR & IR Advisor 
 Walbrook PR                       [phone] or [e-mail] 
                                          [phone] / [phone] 
 Paul McManus/Lianne Cawthorne                                              303 
 

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives . The Group's lead product, Feraccru (R) / Accrufer (R) has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru (R) with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer (R) with Shield currently in the process of selecting a commercialisation partner. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information please visit www.shieldtherapeutics.com

About Feraccru (R) /Accrufer(R)

Feraccru (R) /Accrufer(R) is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials, including positive results from the Phase IIIb AEGIS-H2H study in which Feraccru (R) /Accrufer(R) demonstrated it was non-inferior in delivering improvements in haemoglobin levels compared to intravenously-administered (IV) Ferinject(R)/Injectafer(R) (ferric carboxymaltose). Feraccru (R) /Accrufer(R) therefore offers a compelling alternative to IV iron for those patients unable to tolerate salt-based oral iron therapies and wish to avoid the complexities of infusion-based iron therapies.

When salt-based oral iron therapies are ingested they can cause a range of mild-to-severe gastrointestinal tract (GI) adverse events, including nausea, bloating and constipation through the release and subsequent reactivity of free iron in the GI tract, leading to poor tolerability, reduced patient compliance and ultimately treatment failure. Feraccru (R) /Accrufer(R) is not an iron salt and, as a result, it does not routinely cause the same treatment-limiting intolerance issues of salt-based iron therapies, whilst the iron from the ferric maltol molecule can be readily absorbed.

Prior to Feraccru (R) /Accrufer(R) , IV iron therapies were the only realistic alternative treatment option for iron deficient patients with or without anaemia intolerant of or unwilling to be treated salt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for these patients to have access to an effective therapy that is well tolerated, convenient and does not require hospital-based administration. Feraccru (R) /Accrufer(R) meets those requirements.

About Iron Deficiency

The WHO states that iron deficiency is the most common and widespread nutritional disorder in the world. As well as affecting a large number of women and children in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialised nations. There are no current global figures for iron deficiency but, using anaemia as an indirect indicator, it can be estimated that most preschool children and pregnant women in non-industrialised countries, together with at least 30-40% in industrialized countries, are iron deficient.

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the commercial strategy for Feraccru(R)/ Accrufer(R) These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with, the Group's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ALSQLLFBBXLXBBK

(END) Dow Jones Newswires

March 02, 2020 11:41 ET (16:41 GMT)